Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
30
Recruiting, any sponsor type, condition "osteoporosis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed626
30 trials
Showing 1 to 25, recently updated first.
- A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without FracturesPivotal-lookingRecruiting
Odense University HospitalAcademic, hospital or other
NCT06864130 · 1,400 participants (planned) · Start Feb 21, 2025 · Primary completion Mar 1, 2029
Drug: Alendronate 70mg weekly · For: Osteoporosis in Post-menopausal Women
Sites: Aalborg, Denmark; Copenhagen, Denmark; Esbjerg, Denmark · 8 sites in all
Johns Hopkins UniversityAcademic, hospital or other
NCT05704036 · 75 participants (planned) · Start May 2, 2023 · Primary completion Jan 2028
Drug: Transdermal estrogen; Progesterone · For: Cystic Fibrosis; Hypoestrogenism
Sites: Baltimore, Maryland
Prof Dr Frank ButtgereitAcademic, hospital or other
NCT02719314 · 10,000 participants (planned) · Start Dec 2015 · Primary completion Jul 2029
Drug: Glucocorticoid treatment · For: Osteoporosis; Inflammatory Rheumatism
Sites: Berlin, Germany
- Combined Anabolic TherapyRecruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06558188 · 50 participants (planned) · Start Feb 3, 2025 · Primary completion Nov 2, 2027
Drug: Romosozumab; Teriparatide · For: Osteoporosis, Postmenopausal; Osteoporosis
Sites: Boston, Massachusetts
- Preserving Geriatric Muscle With an Osteoporosis MedicationPivotal-lookingRecruiting
Chrissy KistlerAcademic, hospital or other
NCT06118905 · 155 participants (planned) · Start Feb 8, 2024 · Primary completion Feb 28, 2029
Drug: Denosumab 60 MG/ML; Zoledronic Acid 5Mg/Bag 100Ml Infusion · For: Osteoporosis
Sites: Pittsburgh, Pennsylvania
Duke UniversityAcademic, hospital or other
NCT06041789 · 45 participants (planned) · Start Feb 3, 2025 · Primary completion Sep 2027
Drug: Donepezil; Memantine · For: Osteoporosis
Sites: Durham, North Carolina
- RANK-ligand Inhibition to Combat Sarcopenia With Underlying OsteoporosisPivotal-lookingRecruiting
Prince of Wales Hospital, Shatin, Hong KongAcademic, hospital or other
NCT06643780 · 120 participants (planned) · Start Apr 9, 2024 · Primary completion Apr 2027
Drug: Denosumab; Zolendronic Acid · For: Sarcopenia in Elderly
Sites: Hong Kong, China
Pennington Biomedical Research CenterAcademic, hospital or other
NCT07154719 · 50 participants (planned) · Start Oct 9, 2025 · Primary completion Feb 1, 2027
Drug: Tirzepatide · For: Musculoskeletal Abnormalities; Obesity; Sarcopenic Obesity and 2 more
Sites: Baton Rouge, Louisiana; Scarborough, Maine
National Taiwan University HospitalAcademic, hospital or other
NCT07406685 · 52 participants (planned) · Start Aug 20, 2026 · Primary completion Aug 31, 2030
Drug: Ibandronate IV; Zoledronic acid IV · For: Postmenopausal Osteoporosis; Postmenopausal Osteopenia; Primary Osteoporosis and 1 more
Sites: Taipei, Taiwan
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT07776613 · 25 participants (planned) · Start Aug 17, 2026 · Primary completion Aug 2028
Drug: Romosozumab · For: Breast Cancer; Metastatic Breast Cancer (MBC)
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 7 sites in all
Diakonhjemmet HospitalAcademic, hospital or other
NCT06395883 · 160 participants (planned) · Start Jan 1, 2025 · Primary completion Oct 2027
Drug: Glucocorticoid Effect · For: Osteoporosis; Osteoporosis, Steroid Induced; Inflammatory Rheumatism
Sites: Drammen, Norway; Oslo, Norway
- Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal FemalesPivotal-lookingRecruiting
University of ConnecticutAcademic, hospital or other
NCT07365514 · 159 participants (planned) · Start Jul 2026 · Primary completion Feb 2028
Drug: Blackcurrant (BC) extract; Blackcurrant (BC) extract and 1 more · For: Postmenopausal Osteoporosis; Gut Microbiome; Menopause
Sites: Storrs, Connecticut
424 General Military HospitalAcademic, hospital or other
NCT06164795 · 150 participants (planned) · Start Nov 25, 2023 · Primary completion Jun 1, 2027
Drug: Zoledronate; Denosumab and 3 more · For: Osteoporosis, Postmenopausal
Sites: Athens, Greece; Thessaloniki, Greece; Milan, Italy · 8 sites in all
- The Optimised Use of Romozosumab StudyPivotal-lookingRecruiting
University of AarhusAcademic, hospital or other
NCT06059222 · 270 participants (planned) · Start Oct 2, 2023 · Primary completion Aug 31, 2030
Drug: Romosozumab; Zoledronate and 4 more · For: Osteoporosis
Sites: Aarhus, Denmark
National Taiwan University HospitalAcademic, hospital or other
NCT06938152 · 70 participants (planned) · Start Apr 8, 2025 · Primary completion Apr 30, 2029
Drug: Romosozumab followed by Denosumab; Romosozumab and Denosumab Cycle Therapy · For: Osteoporosis; Osteoporosis Postmenopausal
Sites: Taipei, Taiwan
- Bone, Exercise, Alendronate, and Caloric RestrictionPivotal-lookingRecruiting
Wake Forest University Health SciencesAcademic, hospital or other
NCT05764733 · 900 participants (planned) · Start Jun 8, 2023 · Primary completion Jan 2028
Drug: Bisphosphonate · For: Bone Loss
Sites: Aurora, Colorado; Winston-Salem, North Carolina
- A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing RegimensPivotal-lookingRecruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07579936 · 200 participants (planned) · Start Apr 30, 2026 · Primary completion Jul 30, 2026
Drug: SAL056 56.5μg; Intervention Group 1 and 2 more · For: Postmenopausal Women With Osteoporosis
Sites: Beijing, China
University of Texas Southwestern Medical CenterAcademic, hospital or other
NCT03921060 · 100 participants (planned) · Start Sep 2, 2021 · Primary completion Jul 2027
Drug: Denosumab · For: Cystic Fibrosis
Sites: Dallas, Texas
- Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal WomenPivotal-lookingRecruiting
Odense University HospitalAcademic, hospital or other
NCT07191353 · 148 participants (planned) · Start Oct 20, 2025 · Primary completion Mar 1, 2027
Drug: Everolimus; Placebo · For: Healthy; Osteopenia; Osteoporosis Risk
Sites: Bispebjerg, Denmark; Odense, Denmark
University Hospital, ToulouseAcademic, hospital or other
NCT05039216 · 2,000 participants (planned) · Start Sep 13, 2021 · Primary completion Sep 2, 2026
Drug: Blood sampling · For: Rheumatoid Arthritis; Psoriatic Arthritis; Spondyloarthritis and 1 more
Sites: Toulouse, France
- Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill AdultsPivotal-lookingRecruiting
Australian and New Zealand Intensive Care Research CentreAcademic, hospital or other
NCT04608630 · 450 participants (planned) · Start Jul 15, 2021 · Primary completion Feb 28, 2027
Drug: Denosumab 60 MG/ML; Zoledronic Acid 5Mg/Bag 100Ml Inj and 2 more · For: Critical Illness; Osteoporosis
Sites: Sydney, Australia; Wollongong, Australia; Birtinya, Australia · 22 sites in all
- COMPASS - COpenhagen MenoPAuSe StudyPivotal-lookingRecruiting
Martin Blomberg JensenAcademic, hospital or other
NCT07254429 · 192 participants (planned) · Start Oct 2, 2025 · Primary completion Dec 2027
Drug: Triptorelin 11.25 mg; Sodium Chloride 0.9% and 3 more · For: Menopausal Osteoporosis; Bone Markers
Sites: Herlev, Denmark
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic RefracturePivotal-lookingRecruiting
Peking Union Medical College HospitalAcademic, hospital or other
NCT05866029 · 2,478 participants (planned) · Start May 26, 2023 · Primary completion Sep 30, 2026
Drug: Denosumab; Teriparatide · For: Osteoporotic Fractures
Sites: Beijing, China; Changchun, China; Changsha, China · 58 sites in all
- StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosisPivotal-lookingRecruiting
University Hospital, ToulouseAcademic, hospital or other
NCT06767150 · 200 participants (planned) · Start Oct 2, 2025 · Primary completion Oct 2030
Drug: a second infusion of ZOL when crosslaps levels reach 300 pg/mL; a rescue second infusion at month-12 (standard traitment) · For: Postmenopausal Osteoporosis
Sites: Amiens, France; Bordeaux, France; Cahors, France · 17 sites in all
National Taiwan University HospitalAcademic, hospital or other
NCT07283887 · 90 participants (planned) · Start Dec 3, 2025 · Primary completion Jul 31, 2026
Drug: Denosumab; Romosozumab · For: Osteoporosis
Sites: Douliu, Taiwan
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.